Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Vidutolimod + Nivolumab in Stage IIIB-D Melanoma
NCT03618641Phase 2Completed
- Start
- Aug 2018
- Primary completion
- Aug 2020
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Recombinant Protein Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of vidutolimod in melanoma. Started Aug 2018; status: completed.
02
Drugs
vidutolimod
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT03618641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03618641.